6-K ·Filed Apr 15, 2026
Notable filing: 6-K
Actionable Insight ▲ Bullish
The acquisition of CAR technology could significantly enhance Mesoblast's product pipeline and competitive position in cell therapies, though the share issuance may lead to dilution.
Final — all horizons settled through T+60d
MEOBF ▼ -3.13% at T+60d
LONG call ✗ call lost -3.13% · α vs SPY -11.26% · entry $1.60 → $1.55
T+1d
0.00%
call 0.00% · α -0.25%
$1.60
settled 6mo ago
T+5d
+6.25%
call +6.25% · α +4.61%
$1.70
settled 6mo ago
T+20d
+6.25%
call +6.25% · α +0.21%
$1.70
settled 6mo ago
T+60d
-3.13%
call -3.13% · α -11.26%
$1.55
settled 4mo ago
Price Chart
Loading chart...
Executive Summary
Mesoblast Limited has acquired an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform from Mayo Clinic, enhancing its mesenchymal lineage stromal cell (MSC) products. The acquisition was made through the issuance of ASX ordinary shares.
Key Facts
- Acquired exclusive worldwide license to patented CAR technology platform
- Technology aims to enhance targeting and potency of MSC products
- Acquisition accomplished through issuance of ASX ordinary shares
- Mayo Clinic will provide in-kind support for technology advancement
- Potential applications include ulcerative colitis, Crohn's disease, and lupus nephritis
Financial Impact
Acquisition made through issuance of ASX ordinary shares
dilutionintellectual_property
Risk Factors
- Dilution from issuance of new shares
- Uncertainty in successful integration and commercialization of the technology
- Dependence on Mayo Clinic's in-kind support
Market Snapshot
Exchange
OTC
Sector
Biological Products, (No Diagnostic Substances)
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001345099-26-000047 |
| Exhibit: exhibit991caracquisition.htm | 0001345099-26-000047 |
| Document: 0001345099-26-000047-index-headers.html | 0001345099-26-000047 |
| Document: 0001345099-26-000047-index.html | 0001345099-26-000047 |
| Document: 0001345099-26-000047.txt | 0001345099-26-000047 |
8 reports for MEOBF
60% Hit rate @ T+20 Went positive at some point 4 of 5 best @ T+60▲ +22.58%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 10, 2026 19w ago | 6-K | $1.55 $1.55 | · 0.00% | ▼ −3.89% | $1.32 (−14.84%) |
Apr 30, 2026 25w ago | 6-K | $1.70 $1.70 | · 0.00% | ▼ −5.23% | $1.32 (−22.35%) |
Apr 16, 2026 27w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▲ +0.88% | $1.32 (−17.50%) |
Apr 15, 2026 27w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▲ +0.21% | $1.32 (−17.50%) |
Apr 8, 2026 28w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.32 (−17.50%) |
Apr 8, 2026 28w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.32 (−17.50%) |
Apr 8, 2026 28w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.32 (−17.50%) |
Apr 8, 2026 28w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.32 (−17.50%) |
Showing 8 of 8
US Market Status
Market Closed — Opens Wed (15h 34m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers